BMY Technical Analysis
As of date:2/6/2023
BMY stock price:74.53
BMY 50 DMA:74.43
BMY 200 DMA:73.39
BMY MACD (200-50):-1.04
BMY RSI:59.82
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)59.82
Extremely
Oversold

Also see:
BMY Market Cap History
BMY Shares Outstanding History
BMY YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree BMY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Trupanion (TRUP) Shares Cross Below 200 DMA
1 hour, 20 minutes ago


CHS Breaks Below 200-Day Moving Average - Notable for CHSCM
1 hour, 20 minutes ago


NUVA Makes Notable Cross Below Critical Moving Average
1 hour, 23 minutes ago


PRTS Crosses Below Key Moving Average Level
1 hour, 23 minutes ago


Mesa Laboratories (MLAB) Shares Cross Below 200 DMA
1 hour, 30 minutes ago


Notable Two Hundred Day Moving Average Cross - ENFN
1 hour, 36 minutes ago


BlackRock Municipal Target Term Trust Breaks Below 200-Day Moving Average - Notable for BTT
1 hour, 43 minutes ago


First Trust Dorsey Wright Dynamic Focus 5 (FVC) Shares Cross Below 200 DMA
1 hour, 43 minutes ago


FCTR Crosses Below Key Moving Average Level
1 hour, 56 minutes ago


Notable Two Hundred Day Moving Average Cross - AVY
1 hour, 56 minutes ago


Cohen & Steers Total Return Realty Fund (RFI) Shares Cross Below 200 DMA
1 hour, 56 minutes ago


Notable Two Hundred Day Moving Average Cross - VBND
2 hours ago


Loblaw Companies (L.CA) Shares Cross Above 200 DMA
2 hours, 4 minutes ago


Sonos Inc Breaks Below 200-Day Moving Average - Notable for SONO
4 hours, 28 minutes ago


The Trade Desk Breaks Below 200-Day Moving Average - Notable for TTD
4 hours, 30 minutes ago


More Technical Analysis News

BMY Technical AnalysisBMY RSI
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

When researching a stock like Bristol-Myers Squibb, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BMY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BMY stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
BMY DMABMY MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BSX Technical Analysis
CAH Technical Analysis
CI Technical Analysis
CNC Technical Analysis
COO Technical Analysis
CRL Technical Analysis
CTLT Technical Analysis
CVS Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
More Healthcare companies »

 

BMY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2023, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.